News
Anthem Biosciences Launches Veeva Vault Quality for Greater Efficiency and Compliance
Veeva Systems announced that Anthem Biosciences, a rapidly expanding contract research and innovation service provider (CRISP), has successfully implemented Veeva Vault Quality across all its manufacturing and research operations. With Veeva Vault QualityDocs and Veeva Vault Training, Anthem Biosciences...
IT & Data Management
Tech Trends That May Shape-Up The Pharma Sector In 2024
It is well worth noting that the last few years have seen a rapid period when it comes to technological adoption in the life sciences sector, mostly pushed by the pandemic. As the industry moves on, it is bent...
News
Worldwide Pharma May Intensify Further In The Time To Come
Massive transitions in the healthcare market have gone on to push the pharma sector into some painful shifts in the years that have gone by. It is quite evident that the traditional commercial model has gone on to get...
Drug Research
Europe Publishes The First List of Essential Medicines
Along with the European Commission, the Heads of Medicines Agencies- HMA as well as the European Medicines Agency-EMA have gone on to publish the first Union list of critical medicines.
The list goes on to contain over 200 active substances...
News
American Scientist Federation Addresses AI Biosecurity Risks
The Federation of American Scientists- FAS has gone on to publish five policy recommendations so as to address the issues concerning AI when it comes to life sciences.
It is well to be noted that the Bio X AI policy...
News
Aptamer Group signs material agreement with genetic medicines company
Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces that it has entered into a material agreement with a biotechnology company developing genetic medicines.
Under the terms of the agreement, Aptamer...
News
Healthy M&A Expected In Pharma-Life Sciences Sectors In 2024
In all probabilities, it is expected that mergers & acquisitions in the pharma and life sciences sectors will hit a healthy level in 2024, with deals reaching $225 billion to $275 billion, according to PwC's new US Deals 2024...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















